Boston Scientific (BSX) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Boston Scientific Corporation (BSX) insider buying and selling: 10 purchases, 8 sales
122 Form 4 Table I transactions filed with the SEC by Boston Scientific Corporation insiders between 2025-09-03 and 2026-09-03 (15-month history): 10 open-market purchases and 8 sales, plus 104 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $15.0M by Mahoney Michael F on 2026-02-02.
Boston Scientific insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Boston Scientific insiders filed 10 purchases worth $10.0M and 6 sales worth $24.3M on the open market. The net balance is on the sell side: $14.3M more sold than bought.
The biggest buyer was Mahoney Michael F (Chairman, President & CEO): $9.0M in 1 purchase, out of 5 different buyers. The biggest seller was Mahoney Michael F (Chairman, President & CEO): $15.0M in 1 sale, out of 4 different sellers.
The largest trade of the period was a sale of $15.0M on Feb 2, 2026, by Mahoney Michael F (Chairman, President & CEO), under a 10b5-1 plan. Form 4 on sec.gov (0001225208-26-001156).
All 6 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 6 purchases and 0 sales, against 4 and 0 in the three before. The latest purchase is from Aug 25, 2026; the latest sale from Feb 2, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Boston Scientific has more sales than 21 of the other 58, ranks 32 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Boston Scientific included.
The 20 most important trades
The 10 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 122 BSX trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-03 | 2026-08-05 | Mahoney Michael F | Chairman, President & CEO | $9.0M | P — Open-market purchaseForm 4 footnoteF1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-07-31 | 2026-08-03 | Ludwig Edward J | Director | $227k | P — Open-market purchase | SEC |
| 2026-05-20 | 2026-05-21 | Ludwig Edward J | Director | $203k | P — Open-market purchase | SEC |
| 2026-05-20 | 2026-05-21 | Habiger David C | Director | $126k | P — Open-market purchaseForm 4 footnoteF2 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $55.85 to $56.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-05-19 | 2026-05-21 | Habiger David C | Director | $125k | P — Open-market purchaseForm 4 footnoteF1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.93 to $56.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-08-25 | 2026-08-26 | Morano Susan E | Director | $100k | P — Open-market purchase | SEC |
| 2026-05-20 | 2026-05-21 | Pegus Cheryl | Director | $100k | P — Open-market purchaseForm 4 footnoteF1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-08-05 | 2026-08-07 | Habiger David C | Director | $100k | P — Open-market purchaseForm 4 footnoteF1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.21 to $47.98, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-08-03 | 2026-08-05 | Habiger David C | Director | $50k | P — Open-market purchaseForm 4 footnoteF1 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-08-04 | 2026-08-05 | Habiger David C | Director | $7k | P — Open-market purchaseForm 4 footnoteF2 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. | SEC |
| 2026-02-02 | 2026-02-03 | Mahoney Michael F | Chairman, President & CEO | $15.0M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 29, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.985, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-09-02 | 2025-09-03 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | $5.3M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.32 to $105.25 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.32 to $106.27, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-11-03 | 2025-11-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | $5.0M | S — Open-market sale (scheduled 10b5-1)4 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-10-01 | 2025-10-01 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | $4.9M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.86 to $98.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.86 to $98.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-12-01 | 2025-12-02 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | $1.8M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.11 to $101.89, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-11-06 | 2025-11-06 | Zane Ellen M | Director | $1.3M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.89 to $98.65, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-10-27 | 2025-10-28 | Zane Ellen M | Director | $1.0M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.57 to $101.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2025-10-28 | 2025-10-28 | Zane Ellen M | Director | $297k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.165 to $102.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-02-13 | 2026-02-18 | Mahoney Michael F | Chairman, President & CEO | $9.9M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-07-31 | 2026-08-03 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | $3.0M | I — Discretionary transaction in a plan Indirect holding, through: By 401(k) 2 Form 4 footnotesF1 Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 3, 2025 and Sep 3, 2026, Boston Scientific Corporation open-market activity adds up to 10 purchases worth $10.0M and 8 sales worth $34.5M. The net balance is $24.5M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Boston Scientific Corporation's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 42 | $6.8M |
| F | Tax withholding (shares surrendered for taxes) | 37 | $18.4M |
| A | Grant or award | 13 | $0 |
| P | Open-market purchase | 10 | $10.0M |
| S | Open-market sale | 8 | $34.5M |
| G | Gift | 6 | $0 |
| I | Discretionary transaction in a plan | 5 | $5.2M |
| J | Other transaction (explained in the filing) | 1 | $0 |
| Total | Everything filed in the period | 122 | $75.1M |
57 of the 122 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 16 distinct people or entities have filed Boston Scientific Corporation transactions: 5 bought on the open market and 4 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Mahoney Michael F | Chairman, President & CEO | 16 | $9.0M (1) | $15.0M (1) | 2026-08-05 |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 18 | — | $15.2M (3) | 2026-08-03 |
| Zane Ellen M | Director | 5 | — | $2.6M (3) | 2026-05-11 |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 14 | — | $1.8M (1) | 2026-05-04 |
| Ludwig Edward J | Director | 3 | $430k (2) | — | 2026-08-03 |
| Habiger David C | Director | 6 | $408k (5) | — | 2026-08-07 |
| Morano Susan E | Director | 3 | $100k (1) | — | 2026-08-26 |
| Pegus Cheryl | Director | 1 | $100k (1) | — | 2026-05-21 |
Shown here are the 8 who moved the most money, out of 16. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 5 purchases and 0 sales, worth $9.3M. 7 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $5.3M |
| Oct 2025 | 0 | $0 | 3 | $6.2M |
| Nov 2025 | 0 | $0 | 2 | $6.2M |
| Dec 2025 | 0 | $0 | 1 | $1.8M |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $15.0M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 4 | $554k | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 1 | $227k | 0 | $0 |
| Aug 2026 | 5 | $9.3M | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Boston Scientific Corporation (BSX) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
8 of the 8 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Boston Scientific's 10 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Sep 3, 2026, and a Form 4 arrives up to two business days after the trade.
16 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.